ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.52
-1.13%
US Tech 100
20,263.20
-1.69%
S&P 500
5,827.04
-1.54%
US Dollar vs CAD
1.4426
0.00%
Bitcoin
94,516.36
-0.06%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Exscientia PLC (EXAI)

  7. Exscientia PLC (EXAI) News

EXAI

Exscientia (EXAI)

Exscientia PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EXAI
DateTimeSourceHeadlineSymbolCompany
12/02/20247:39AMEdgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EXAIExscientia PLC
11/22/20247:00PMEdgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:EXAIExscientia PLC
11/20/20249:01AMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EXAIExscientia PLC
11/20/20248:53AMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EXAIExscientia PLC
11/20/20248:20AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
11/20/20246:00AMGlobeNewswire Inc.Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNASDAQ:EXAIExscientia PLC
11/13/20249:37AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
11/12/20243:55PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
11/08/20245:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
11/06/20245:08AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
10/24/20243:00PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXAIExscientia PLC
10/16/20248:49PMBusiness WireExscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec SanofiNASDAQ:EXAIExscientia PLC
10/16/20248:35PMBusiness WireExscientia erreicht Meilensteine ​​für zwei Programme im Rahmen der Zusammenarbeit mit SanofiNASDAQ:EXAIExscientia PLC
10/16/20246:00AMBusiness WireExscientia Achieves Milestones for Two Programmes in Sanofi CollaborationNASDAQ:EXAIExscientia PLC
10/10/20245:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
10/09/20242:25PMBusiness WireExscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-InhibitorenNASDAQ:EXAIExscientia PLC
10/09/20242:25PMBusiness WireExscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024NASDAQ:EXAIExscientia PLC
10/09/20246:00AMBusiness WireExscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024NASDAQ:EXAIExscientia PLC
08/30/20247:57AMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:EXAIExscientia PLC
08/28/20243:42PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
08/28/202411:11AMBusiness WireExscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführenNASDAQ:EXAIExscientia PLC
08/28/202411:11AMBusiness WireExscientia participera à la 22e conférence annuelle de Morgan Stanley sur les soins médicaux dans le mondeNASDAQ:EXAIExscientia PLC
08/28/20246:00AMBusiness WireExscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:EXAIExscientia PLC
08/23/20243:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXAIExscientia PLC
08/15/20246:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
08/15/20246:00AMBusiness WireExscientia Business Update for Second Quarter and First Half 2024NASDAQ:EXAIExscientia PLC
08/09/20244:44AMIH Market NewsTSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and MoreNASDAQ:EXAIExscientia PLC
08/08/20244:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
08/08/20246:39AMGlobeNewswire Inc.Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesNASDAQ:EXAIExscientia PLC
07/24/20243:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXAIExscientia PLC
 Showing the most relevant articles for your search:NASDAQ:EXAI

Your Recent History

LSE
PH87
Westp. Sec 27
LSE
SM90
Morhomes 53
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads